Executive Summary
CGI Federal Inc., a Timken Company subsidiary, secured a $108M GSA delivery order for EPA IT enterprise development, with potential expansion to $523M through options to 2030. This bullish signal highlights strength in government IT services amid steady federal spending. Investors should monitor option exercises for revenue upside, tempered by execution risks from subawards and performance fees.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Mega Contracts Monitor ($100M+) digest from March 27, 2026.
Investment Signals (1)
- CGI Federal Wins $108M EPA IT Contract with $523M Potential (HIGH)▲
GSA award under full competition for computer systems design services, obligated $108M with options to $523M by 2030.
Risk Flags (1)
- Execution [MEDIUM RISK]▼
Options may not be exercised beyond 2026 end date; award fees tied to performance evaluations; $15M subawards across 47 recipients could pressure margins.
Opportunities (1)
- ◆
Potential exercise of options to unlock full $523M value by 2030 in EPA IT support via GSA task orders.
Sector Themes (1)
- ◆
GSA FAS awards signal sustained EPA investment in enterprise IT development under NAICS 541512.
Watch List (1)
- 👁
{"entity"=>"CGI Federal Inc. / The Timken Company", "reason"=>"High potential value from options in stable federal IT stream.", "trigger"=>"Option exercises or new GSA task orders exceeding $100M"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Mega Contracts Monitor ($100M+)
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals